Antibody Development
We enable the development of human antibodies for prevention, treatment, and cure of infectious diseases.
Antibody development is often delayed due to various challenges, including detailed antibody profiling and complex regulatory requirements.
At Togontech, we are committed to overcoming these hurdles to accelerate development—so that antibodies can be deployed directly to patients without delay. To achieve this, we offer targeted expertise across key stages of human monoclonal antibody development.
In the preclinical phase, we provide comprehensive in vitro and in vivo characterization of antibody candidates. This includes custom-designed neutralization assays using both replication-competent and pseudotype virus systems. We also perform pharmacokinetic analyses in a variety of mouse models and utilize HIV-1–infected humanized mice to assess the efficacy of broadly neutralizing antibodies.
These studies also include profiling viral escape mechanisms in response to single or combination antibody therapies. For clinical development, we support both observational and early-phase interventional studies, offering strategic guidance on study design, implementation, and execution.
Our team combines deep scientific expertise with strong operational know-how to advance your antibody-based solutions against infectious diseases.